Inventor · disambiguated record
Pingyu Zhong
Also filed as: ZHONG PINGYU
20 granted patents·10 pending applications·828 citations·filing 2001–2021
96Inventor score
Top patents by PatentIndex Score
30 records- 0197US6833441B2Compositions and methods for generating chimeric heteromultimersABMAXIS INC·Filed 2001·Granted Dec 21, 2004·293 cites·38 claims
- 0295US8188233B21B20 PCSK9 antagonistsCONDRA JON H·Filed 2009·Granted May 29, 2012·91 cites·22 claims
- 0395US8188234B21D05 PCSK9 antagonistsCONDRA JON H·Filed 2009·Granted May 29, 2012·98 cites·19 claims
- 0495US7429652B2Compositions and methods for generating chimeric heteromultimersABMAXIS INC·Filed 2004·Granted Sep 30, 2008·78 cites·31 claims
- 0595US7117096B2Structure-based selection and affinity maturation of antibody libraryABMAXIS INC·Filed 2002·Granted Oct 3, 2006·141 cites·46 claims
- 0693US7667004B2Humanized antibodies against vascular endothelial growth factorABMAXIS INC·Filed 2003·Granted Feb 23, 2010·59 cites·9 claims
- 0789US8697070B21D05 PCSK9 antagonistsCONDRA JON H·Filed 2012·Granted Apr 15, 2014·15 cites·6 claims
- 0886US10919962B2Method of reducing tumor growth with IL-1beta neutralizing human monoclonal antibodiesAGENCY SCIENCE TECH & RES·Filed 2018·Granted Feb 16, 2021·4 cites·14 claims
- 0984US10167335B2IL-1β neutralizing human monoclonal antibodiesAGENCY SCIENCE TECH & RES·Filed 2013·Granted Jan 1, 2019·6 cites·17 claims
- 1084US7462698B2Anti-CD26 antibodies and methods of use thereofY S THERAPEUTICS CO LTD·Filed 2006·Granted Dec 9, 2008·11 cites·33 claims
- 1181US8030469B2Anti-CD26 antibodies and methods of use thereofSBI INCUBATION CO LTD·Filed 2008·Granted Oct 4, 2011·4 cites·2 claims
- 1279US7175983B2Adapter-directed display systemsABMAXIS INC·Filed 2001·Granted Feb 13, 2007·13 cites·44 claims
- 1378US8802827B2AX1 PCSK9 antagonistsLUO PETER PEIZHI·Filed 2010·Granted Aug 12, 2014·6 cites·9 claims
- 1478US7910350B2Adaptor-directed helper systemsABMAXIS INC·Filed 2005·Granted Mar 22, 2011·2 cites·11 claims
- 1574US11912761B2IL-1β neutralizing human monoclonal antibodiesAGENCY SCIENCE TECH & RES·Filed 2021·Granted Feb 27, 2024·0 cites·18 claims
- 1674US11702471B2IL-1β neutralizing human monoclonal antibodiesAGENCY SCIENCE TECH & RES·Filed 2021·Granted Jul 18, 2023·0 cites·20 claims
- 1773US11780913B2IL-1β neutralizing human monoclonal antibodiesAGENCY SCIENCE TECH & RES·Filed 2020·Granted Oct 10, 2023·0 cites·9 claims
- 1873US8957194B21B20 PCSK9 antagonistsCONDRA JON H·Filed 2012·Granted Feb 17, 2015·2 cites·7 claims
- 1970US8877900B2AX132 PCSK9 antagonistsLUO PETER PEIZHI·Filed 2010·Granted Nov 4, 2014·4 cites·9 claims
- 2065US8637435B2Eukaryotic cell display systemsWANG KEVIN CAILI·Filed 2008·Granted Jan 28, 2014·1 cites·6 claims
- 2165US2004010376A1Generation and selection of protein library in silicoFiled 2003·Application pending·0 cites
- 2263US2007037214A1Generation and selection of protein library in silicoLUO PEIZHI·Filed 2006·Application pending·0 cites
- 2363US2007037217A1Structure-based selection and affinity maturation of antibody libraryLUO PEIZHI·Filed 2006·Application pending·0 cites
- 2461US2011124528A1Generation and affinity maturation of antibody library in silicoLUO PEIZHI·Filed 2010·Application pending·0 cites
- 2561US2012129702A1Structure-Based Selection and Affinity Maturation of Antibody LibraryLUO PEIZHI·Filed 2010·Application pending·0 cites
- 2656US2014220027A11d05 pcsk9 antagonistsMERCK SHARP & DOHME·Filed 2014·Application pending·0 cites
- 2753US2003022240A1Generation and affinity maturation of antibody library in silicoFiled 2002·Application pending·0 cites
- 2849US2012329679A1Eukaryotic cell display systemsWANG KEVIN CAILI·Filed 2012·Application pending·0 cites
- 2942US2009082221A1Cross-Species and Multi-Species Display SystemsWANG KEVIN CAILI·Filed 2007·Application pending·0 cites
- 3035US2014121123A1Methods for diversifying antibodies, antibodies derived therefrom and uses thereofWANG KEVIN CAILI·Filed 2011·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →